Study: Psilocybin enhances therapy in patients with major depression
The Brown University Psychopharmacology Update January 7, 2021 DOI: 10.1002/pu.30675 via OpenAlex
Summary
AI-generated from the abstractPatients with major depressive disorder who received two administrations of the psychedelic psilocybin as part of a psychotherapy regimen experienced rapid and lasting improvement in depression symptoms, according to a randomized open-label trial. These findings extend previous research suggesting antidepressant effects for psilocybin in patients with cancer and treatment-resistant depression. Results were published online November 4, 2020, in JAMA Psychiatry.
Study at a glance
| Characteristics | Randomized open-label trial Peer reviewed |
|---|---|
| Population | Patients with major depressive disorder |
| Intervention | Psilocybin |
| Topics | Anxiety Depression Psilocybin |
| Keywords | Depression economics Psychiatry Antidepressant |
| Key finding | Two administrations of psilocybin as part of a psychotherapy regimen led to rapid and lasting improvement in depression symptoms in patients with major depressive disorder. |
Abstract
Patients with major depressive disorder who received two administrations of the psychedelic psilocybin as part of a psychotherapy regimen saw a rapid and lasting improvement in depression symptoms, a randomized open‐label trial has found. These findings extend results of research that have suggested antidepressant effects for psilocybin in patients with cancer and treatment‐resistant depression, the researchers stated. Study results were published online Nov. 4, 2020, in JAMA Psychiatry .